Benzoheterocyclic Oxime Carbamates Active against Mycobacterium tuberculosis : Synthesis, Structure-Activity Relationship, Metabolism, and Biology Triaging.

Autor: van der Westhuyzen R; Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch, Cape Town 7701, South Africa., Mabhula A; South African Medical Research Council Drug Discovery and Development Research Unit, Department of Chemistry, University of Cape Town, Rondebosch, Cape Town 7701, South Africa., Njaria PM; South African Medical Research Council Drug Discovery and Development Research Unit, Department of Chemistry, University of Cape Town, Rondebosch, Cape Town 7701, South Africa., Müller R; Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch, Cape Town 7701, South Africa., Ngumbu Muhunga D; Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch, Cape Town 7701, South Africa., Taylor D; Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, University of Cape Town, Rondebosch, Cape Town 7701, South Africa., Lawrence N; Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, University of Cape Town, Rondebosch, Cape Town 7701, South Africa., Njoroge M; Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, University of Cape Town, Rondebosch, Cape Town 7701, South Africa., Brunschwig C; Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, University of Cape Town, Rondebosch, Cape Town 7701, South Africa., Moosa A; SAMRC/NHLS/UCT Molecular Mycobacteriology Research Unit, Department of Pathology, University of Cape Town, Rondebosch, Cape Town 7701, South Africa., Singh V; Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch, Cape Town 7701, South Africa.; South African Medical Research Council Drug Discovery and Development Research Unit, Department of Chemistry, University of Cape Town, Rondebosch, Cape Town 7701, South Africa., Rao SPS; Novartis Institute for Tropical Diseases (NITD), 10 Biopolis Road, Chromos #05-01, Singapore 138670, Singapore., Manjunatha UH; Novartis Institute for Tropical Diseases (NITD), 10 Biopolis Road, Chromos #05-01, Singapore 138670, Singapore., Smith PW; Novartis Institute for Tropical Diseases (NITD), 10 Biopolis Road, Chromos #05-01, Singapore 138670, Singapore., Warner DF; SAMRC/NHLS/UCT Molecular Mycobacteriology Research Unit, Department of Pathology, University of Cape Town, Rondebosch, Cape Town 7701, South Africa.; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch, Cape Town 7701, South Africa., Street LJ; Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch, Cape Town 7701, South Africa., Chibale K; Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch, Cape Town 7701, South Africa.; South African Medical Research Council Drug Discovery and Development Research Unit, Department of Chemistry, University of Cape Town, Rondebosch, Cape Town 7701, South Africa.; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch, Cape Town 7701, South Africa.

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2021 Jul 08; Vol. 64 (13), pp. 9444-9457. Date of Electronic Publication: 2021 Jun 17.

Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite Plasmodium falciparum and Optimization Efforts.

Autor: Le Manach C; Drug Discovery and Development Center (H3D), University of Cape Town, Rondebosch 7701, South Africa., Dam J; Drug Discovery and Development Center (H3D), University of Cape Town, Rondebosch 7701, South Africa., Woodland JG; Drug Discovery and Development Center (H3D), University of Cape Town, Rondebosch 7701, South Africa., Kaur G; Drug Discovery and Development Center (H3D), University of Cape Town, Rondebosch 7701, South Africa., Khonde LP; Drug Discovery and Development Center (H3D), University of Cape Town, Rondebosch 7701, South Africa., Brunschwig C; Drug Discovery and Development Center (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory 7925, South Africa., Njoroge M; Drug Discovery and Development Center (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory 7925, South Africa., Wicht KJ; Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, New York 10032, United States., Horatscheck A; Drug Discovery and Development Center (H3D), University of Cape Town, Rondebosch 7701, South Africa., Paquet T; Drug Discovery and Development Center (H3D), University of Cape Town, Rondebosch 7701, South Africa., Boyle GA; Drug Discovery and Development Center (H3D), University of Cape Town, Rondebosch 7701, South Africa., Gibhard L; Drug Discovery and Development Center (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory 7925, South Africa., Taylor D; Drug Discovery and Development Center (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory 7925, South Africa., Lawrence N; Drug Discovery and Development Center (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory 7925, South Africa., Yeo T; Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, New York 10032, United States., Mok S; Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, New York 10032, United States., Eastman RT; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland 20892, United States., Dorjsuren D; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland 20892, United States., Talley DC; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland 20892, United States., Guo H; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland 20892, United States., Simeonov A; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland 20892, United States., Reader J; Department of Biochemistry, Genetics and Microbiology, Institute for Sustainable Malaria Control, University of Pretoria, Hatfield, Pretoria 0028, South Africa., van der Watt M; Department of Biochemistry, Genetics and Microbiology, Institute for Sustainable Malaria Control, University of Pretoria, Hatfield, Pretoria 0028, South Africa., Erlank E; Wits Research Institute for Malaria, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa.; Centre for Emerging Zoonotic and Parasitic Diseases, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg 2192, South Africa., Venter N; Wits Research Institute for Malaria, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa.; Centre for Emerging Zoonotic and Parasitic Diseases, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg 2192, South Africa., Zawada JW; Wits Research Institute for Malaria, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa.; Centre for Emerging Zoonotic and Parasitic Diseases, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg 2192, South Africa., Aswat A; Wits Research Institute for Malaria, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa.; Centre for Emerging Zoonotic and Parasitic Diseases, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg 2192, South Africa., Nardini L; Wits Research Institute for Malaria, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa.; Centre for Emerging Zoonotic and Parasitic Diseases, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg 2192, South Africa., Coetzer TL; Wits Research Institute for Malaria, School of Pathology, Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa., Lauterbach SB; Wits Research Institute for Malaria, School of Pathology, Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa., Bezuidenhout BC; Wits Research Institute for Malaria, School of Pathology, Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa., Theron A; Biosciences, Council for Scientific and Industrial Research, P.O. Box 395, Pretoria 0001, South Africa., Mancama D; Biosciences, Council for Scientific and Industrial Research, P.O. Box 395, Pretoria 0001, South Africa., Koekemoer LL; Wits Research Institute for Malaria, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa.; Centre for Emerging Zoonotic and Parasitic Diseases, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg 2192, South Africa., Birkholtz LM; Department of Biochemistry, Genetics and Microbiology, Institute for Sustainable Malaria Control, University of Pretoria, Hatfield, Pretoria 0028, South Africa., Wittlin S; Swiss Tropical and Public Health Institute, Socinstrasse 57, 4002 Basel, Switzerland.; University of Basel, 4003 Basel, Switzerland., Delves M; Imperial College London, South Kensington, London SW7 2AZ, U.K.; London School of Hygiene and Tropical Medicine, London WC1E 7HT, U.K., Ottilie S; Division of Host-Microbe Systems & Therapeutics, Department of Pediatrics, University of California San Diego, La Jolla, California 92093-076, United States., Winzeler EA; Division of Host-Microbe Systems & Therapeutics, Department of Pediatrics, University of California San Diego, La Jolla, California 92093-076, United States., von Geldern TW; Embedded Consulting, P.O. Box 726, Richmond, Illinois 60071, United States., Smith D; 4 The Maltings, Walmer CT14 7AR, U.K., Fidock DA; Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, New York 10032, United States.; Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, New York 10032, United States., Street LJ; Drug Discovery and Development Center (H3D), University of Cape Town, Rondebosch 7701, South Africa., Basarab GS; Drug Discovery and Development Center (H3D), University of Cape Town, Rondebosch 7701, South Africa., Duffy J; Medicines for Malaria Venture, ICC, Route de Pré-Bois 20, P.O. Box 1826, 1215 Geneva, Switzerland., Chibale K; Drug Discovery and Development Center (H3D), University of Cape Town, Rondebosch 7701, South Africa.; South African Medical Research Council, Drug Discovery and Development Research Unit, Department of Chemistry and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch 7701, South Africa.

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2021 Feb 25; Vol. 64 (4), pp. 2291-2309. Date of Electronic Publication: 2021 Feb 12.

Identification of 2,4-Disubstituted Imidazopyridines as Hemozoin Formation Inhibitors with Fast-Killing Kinetics and In Vivo Efficacy in the Plasmodium falciparum NSG Mouse Model.

Autor: Horatscheck A; Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa., Andrijevic A; Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa., Nchinda AT; Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa., Le Manach C; Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa., Paquet T; Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa., Khonde LP; Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa., Dam J; Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa., Pawar K; Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa., Taylor D; Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, University of Cape Town, Rondebosch 7701, South Africa., Lawrence N; Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, University of Cape Town, Rondebosch 7701, South Africa., Brunschwig C; Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, University of Cape Town, Rondebosch 7701, South Africa., Gibhard L; Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, University of Cape Town, Rondebosch 7701, South Africa., Njoroge M; Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, University of Cape Town, Rondebosch 7701, South Africa., Reader J; Department of Biochemistry, Genetics and Microbiology, Institute for Sustainable Malaria Control, University of Pretoria, Hatfield, Pretoria 0028, South Africa., van der Watt M; Department of Biochemistry, Genetics and Microbiology, Institute for Sustainable Malaria Control, University of Pretoria, Hatfield, Pretoria 0028, South Africa., Wicht K; Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa., de Sousa ACC; Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa., Okombo J; Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa., Maepa K; Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa., Egan TJ; Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch 7701, South Africa., Birkholtz LM; Department of Biochemistry, Genetics and Microbiology, Institute for Sustainable Malaria Control, University of Pretoria, Hatfield, Pretoria 0028, South Africa., Basarab GS; Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa., Wittlin S; Swiss Tropical and Public Health Institute ,Socinstrasse 57, 4002 Basel, Switzerland.; University of Basel, 4002 Basel, Switzerland., Fish PV; Alzheimer's Research UK, UCL Drug Discovery Institute, The Cruciform Building, University College London, Gower Street, London WC1E 6BT, U.K., Street LJ; Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa., Duffy J; Medicines for Malaria Venture, ICC, Route de Pré-Bois 20, P.O. Box 1826, 1215 Geneva, Switzerland., Chibale K; South African Medical Research Council, Drug Discovery and Development Research Unit, Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch 7701, South Africa.

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2020 Nov 12; Vol. 63 (21), pp. 13013-13030. Date of Electronic Publication: 2020 Oct 25.

Investigating Sulfoxide-to-Sulfone Conversion as a Prodrug Strategy for a Phosphatidylinositol 4-Kinase Inhibitor in a Humanized Mouse Model of Malaria.

Autor: Gibhard L; Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, South Africa., Njoroge M; Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, South Africa., Paquet T; Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch, South Africa., Brunschwig C; Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, South Africa., Taylor D; Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, South Africa., Lawrence N; Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, South Africa., Abay E; Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, South Africa., Wittlin S; Swiss Tropical and Public Health Institute, Basel, Switzerland.; University of Basel, Basel, Switzerland., Wiesner L; Department of Medicine, Division of Clinical Pharmacology, University of Cape Town, Observatory, South Africa., Street LJ; Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch, South Africa., Chibale K; Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch, South Africa.; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch, South Africa.; South African Medical Research Council Drug Discovery and Development Research Unit, Department of Chemistry, University of Cape Town, Rondebosch, South Africa., Basarab GS; Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, South Africa greg.basarab@uct.ac.za.

Publikováno v: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2018 Nov 26; Vol. 62 (12). Date of Electronic Publication: 2018 Nov 26 (Print Publication: 2018).

Erratum for Brunschwig et al., "UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria".

Autor: Brunschwig C; Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, South Africa., Lawrence N; Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, South Africa., Taylor D; Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, South Africa., Abay E; Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, South Africa., Njoroge M; Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, South Africa., Basarab GS; Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, South Africa., Le Manach C; Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch, South Africa., Paquet T; Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch, South Africa., Gonzàlez Cabrera D; Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch, South Africa., Nchinda AT; Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch, South Africa., de Kock C; Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, South Africa., Wiesner L; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, South Africa., Denti P; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, South Africa., Waterson D; Medicines for Malaria Venture, Geneva, Switzerland., Blasco B; Medicines for Malaria Venture, Geneva, Switzerland., Leroy D; Medicines for Malaria Venture, Geneva, Switzerland., Witty MJ; Medicines for Malaria Venture, Geneva, Switzerland., Donini C; Medicines for Malaria Venture, Geneva, Switzerland., Duffy J; Medicines for Malaria Venture, Geneva, Switzerland., Wittlin S; Swiss Tropical and Public Health Institute, Basel, Switzerland.; University of Basel, Basel, Switzerland., White KL; Centre for Drug Candidate Optimisation, Monash University, Melbourne, Victoria, Australia., Charman SA; Centre for Drug Candidate Optimisation, Monash University, Melbourne, Victoria, Australia., Jiménez-Díaz MB; GlaxoSmithKline, Tres Cantos Medicines Development Campus, Madrid, Spain., Angulo-Barturen I; GlaxoSmithKline, Tres Cantos Medicines Development Campus, Madrid, Spain., Herreros E; GlaxoSmithKline, Tres Cantos Medicines Development Campus, Madrid, Spain., Gamo FJ; GlaxoSmithKline, Tres Cantos Medicines Development Campus, Madrid, Spain., Rochford R; Department of Immunology and Microbiology, University of Colorado, Aurora, Colorado, USA., Mancama D; Biosciences, Council for Scientific and Industrial Research, Pretoria, South Africa., Coetzer TL; Plasmodium Molecular Research Unit, Wits Research Institute for Malaria, Department of Molecular Medicine and Haematology, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa., van der Watt ME; Department of Biochemistry, Institute for Sustainable Malaria Control and South African Medical Research Council Collaborating Centre for Malaria Research, University of Pretoria, Pretoria, South Africa., Reader J; Department of Biochemistry, Institute for Sustainable Malaria Control and South African Medical Research Council Collaborating Centre for Malaria Research, University of Pretoria, Pretoria, South Africa., Birkholtz LM; Department of Biochemistry, Institute for Sustainable Malaria Control and South African Medical Research Council Collaborating Centre for Malaria Research, University of Pretoria, Pretoria, South Africa., Marsh KC; AbbVie, North Chicago, Illinois, USA., Solapure SM; Nagarjuna Gardens, Bangalore, India., Burke JE; Department of Biochemistry and Microbiology, University of Victoria, Victoria, BC, Canada., McPhail JA; Department of Biochemistry and Microbiology, University of Victoria, Victoria, BC, Canada., Vanaerschot M; Department of Microbiology and Immunology, Columbia University Medical Center, New York, New York, USA., Fidock DA; Department of Microbiology and Immunology, Columbia University Medical Center, New York, New York, USA.; Division of Infectious Diseases, Department of Medicine, Columbia University Medical Center, New York, New York, USA., Fish PV; Alzheimer's Research UK UCL Drug Discovery Institute, Faculty of Brain Sciences, University College London, London, United Kingdom., Siegl P; Siegl Pharma Consulting LLC, Blue Bell, Pennsylvania, USA., Smith DA; Independent Researcher, Walmer, Kent, United Kingdom., Wirjanata G; Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia., Noviyanti R; Eijkman Institute for Molecular Biology, Jakarta, Indonesia., Price RN; Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia.; Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom., Marfurt J; Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia., Silue KD; Centre Suisse de Recherches Scientifiques en Côte d'Ivoire, Abidjan, Côte d'Ivoire., Street LJ; Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch, South Africa., Chibale K; Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch, South Africa kelly.chibale@uct.ac.za.; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch, South Africa.; South African Medical Research Council Drug Discovery and Development Research Unit, Department of Chemistry, University of Cape Town, Rondebosch, South Africa.

Publikováno v: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2018 Oct 24; Vol. 62 (11). Date of Electronic Publication: 2018 Oct 24 (Print Publication: 2018).